603669 Lionco Pharmaceutical Group
- 8.51
- -0.06-0.70%
Lionco Pharmaceutical Group News
Announcement on the proposed selection of subsidiaries participating in the national centralized procurement of pharmaceuticals
Lingkang Pharmaceutical: Announcement on the cancellation of the controlling shareholder\'s share pledge
Announcement on the cancellation of the controlling shareholder\'s share pledge
Lingkang Pharmaceutical: Risk Warning Notice on Stock Trading
Stock Trading Risk Warning Notice
Lingkang Pharmaceutical: Announcement on Abnormal Fluctuations in Stock Trading
Notice of abnormal fluctuations in stock trading
Announcement on pledging some of the shares of the controlling shareholder
Company Report for the Third Quarter of 2024 (after correction)
Announcement on additional information to the 2024 Third Quarter Report
Notice on the Shanghai Stock Exchange\'s response letter to the company\'s third quarter report supervision work letter
An indicative announcement on “Lingkang Bonds Transfer” expected to meet the conversion price correction conditions
Lingkang Pharmaceutical: Convertible Corporate Bond Interest Payment Notice
Convertible Corporate Bonds Interest Payment Notice
Announcement on the receipt of the regulatory work letter on the disclosure of information in the Shanghai Stock Exchange\'s report for the third quarter of 2024
Lingkang Pharmaceutical: Announcement on subsidiary cefuroxime sodium for injection passing the generic drug consistency evaluation
Announcement on the subsidiary\'s injectable cefuroxime passing the generic drug consistency evaluation
Lingkang Pharmaceutical Group Co., Ltd. Investor Relations Activity Record Form for November 3, 2024
Lingkang Pharmaceutical: Third Quarter Report 2024
Third Quarter Report 2024
No Data